在失眠-阿尔茨海默氏病共患症中的 katekins:一个网络药理学和分子对接研究研究
Yuxuan Liu1, Jiaxiu Han2, Shijun Wang1,3
1College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Medicine
|February 24, 2026
概括
katekins 可能通过调节突触修剪来治疗失眠和阿尔茨海默病 (AD). 这项研究确定了与这种复杂的并发症有关的关键目标和途径,提供了新的治疗途径.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 失眠和阿尔茨海默氏症 (AD) 经常共存,由中断的昼夜节律和免疫系统功能障碍联系在一起.
- 强效的多类 catechins 显示出调节这些过程的潜力,但它们的确切机制需要阐明.
研究的目的:
- 确定关键的分子标和信号通路,将甲素化合物与失眠和AD的共同疾病联系起来.
- 在阿尔茨海默病和失眠的背景下,阐明 katechin 作用,昼夜免疫交叉声和突触修剪之间的机制联系.
主要方法:
- 从与失眠和AD相关的昼夜和免疫表型的基因表达差异分析.
- 应用两个机器学习算法来识别关键的分子目标.
- 功能丰富分析 (KEGG,GSEA) 用于确定涉及的信号通路.
主要成果:
- 甲基素 (C) 和基素被确定为昼夜免疫网络的核心组成部分.
- PDE4D,HMOX1和IGF1成为关键标,其中PDE4D是补充途径的核心.
- 观察到补体和PI3K/Akt信号通路的显著丰富.
结论:
- 通过昼夜-免疫交叉声调节,建立了从 катехин到突触修剪调节的机械联系.
- 这种交叉关系控制了微质介导的突触修剪,这对睡眠和神经退行都至关重要.
- 这些发现为管理失眠-AD并发症提供了一种新的治疗策略.
更多相关视频
07:04A High-performance Liquid Chromatography Measurement of Kynurenine and Kynurenic Acid: Relating Biochemistry to Cognition and Sleep in Rats
Published on: August 19, 2018
11.1K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.7K
相关概念视频
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
689
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
689
01:22Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
718
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
718
01:27Insomnia
515
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
Multiple factors contribute...
515
01:26Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
01:19Management of Insomnia
732
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
732